REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Carbohydrate (i.e., Saccharide Radical Containing) Doai Carbohydrate (i.e., Saccharide Radical Containing) DoaiCarbohydrate (i.e., Saccharide Radical Containing) Doai patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027092 - Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders. ... 01/25/07 - 20070021357 - Treatment of inflammatory conditions The invention relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS ... 01/25/07 - 20070021356 - Preemptive prophlyaxis of migraine A method of preventing the headache phase of migraine in a human comprises administration of an anti-convulsant medication to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the anti-convulsant. There is also disclosed a pharmaceutical composition for the ... 01/25/07 - 20070021355 - Antidepressants or foods and beverage for antidepression (wherein R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R5 represents a hydrogen atom, hydroxy, or the like; R6 represents a hydrogen atom, or the like; R7 represents a hydrogen atom or substituted ... 01/18/07 - 20070015717 - 4-[(e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid analogs and method of manufacture and use thereof Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment. ... 01/11/07 - 20070010458 - Drugs for the arthritis treatment or salts thereof, wherein: A contains the radical of a non steroidal antiinflammatory or non steroidal antiinflammatory/analgesic drug, B and C are bivalent linking groups, are used in the arthritis therapy. ... 12/28/06 - 20060293253 - Indole compounds useful for the treatment of cancer The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments. ... 12/28/06 - 20060293252 - Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for their preparation are disclosed. The compounds are suitable, for example, as antidiabetics. ... 12/28/06 - 20060293251 - Substituted indazole-o-glucosides Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. ... 12/28/06 - 20060293250 - Crystalline sugar compositions and method of making Described are novel crystalline pivaloyl furanoses and methods of crystallizing the pivaloyl furanoses. These compounds are useful as intermediates in the synthesis of compounds such as the deoxyjirimycins and nojirimycins and are particularly useful as intermediates for production on a multi-kg scale. Particular crystalline compounds include 1,2,3,6-tetrapivaloyl-α-D-galactofuranose, 1,2,3,6-tetrapivaloyl-α-L-altrofuranose, and 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-α-D-galactofuranose. ... 12/28/06 - 20060293249 - Porphyrin derivatives M is 2H or a metal. ... 12/21/06 - 20060287254 - Use of substituted azetidinone compounds for the treatment of sitosterolemia The present invention is directed to pharmaceutical compositions comprising a sterol absorption inhibitor, a CEPT inhibitor and/or an HMG-CoA reductase inhibitor as well as methods for treating sitosterolemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, mixed dyslopidemia, vascular events prevention and related disorders in a mammal in need thereof by administering said pharmaceutical compositions ... 12/21/06 - 20060287253 - Compounds and methods for treating seizure disorders This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells. ... 12/14/06 - 20060281691 - Method of treating obesity Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof. ... 12/07/06 - 20060276413 - New effector conjugates, methods for their preparation and their pharmaceutical use Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates ... 12/07/06 - 20060276412 - Methods and compositions for managing psychotic disorders Compositions for treating psychotic disorders comprise a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group consisting of ziprasidone, olanzapine and risperidone and the second ingredient comprises at least one anticonvulsant selected from the group consisting of zonisamide and ... 12/07/06 - 20060276411 - Novel non-selective cation channel in neuronal cells and methods for treating brain swelling The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is ... 11/30/06 - 20060270613 - Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for ... 11/30/06 - 20060270612 - Method of modulating stress-activated protein kinase system Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for ... 11/30/06 - 20060270611 - Pediatric formulation of topiramate The present invention concerns a liquid preconcentrate composition comprising topiramate or a pharmaceutically acceptable addition salt thereof as active ingredient and an organic solvent, said composition having a low water content; a liquid composition for oral administration obtainable by mixing the composition with an aqueous medium; and processes for preparing ... 11/30/06 - 20060270610 - Novel compounds for hypoxic cell therapy and imaging The present invention provides for compounds suitable for therapeutic treatment of hypoxic tissues, particularly for application in radiotherapy, chemosensitization, radiosensitization. The present invention further provides for compounds suitable for radioimaging of hypoxic cells. ... 11/23/06 - 20060264382 - 6-amino-6-deoxygalactosylceramides This invention relates to galactosylceramide compounds. ... 11/16/06 - 20060258599 - Methods and composition for the treatment of cystic fibrosis and related illnesses The present invention relates to methods and compositions to treat subjects having cystic fibrosis. These compositions comprise the class of isothiocyanates. Isothiocyanates, absorbed by a cell are conjugated with glutathione GSH by glutathione-s-tranferase (GST). The conjugates are substrates of the multi-drug resistance associated (MRP)/multi-drug resistance (MDR) proteins. These proteins are ... 11/09/06 - 20060252702 - Method of improving cerebral function Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof. ... 11/02/06 - 20060247181 - Tigecycline compositons and methods of preparation The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. ... 11/02/06 - 20060247180 - Purgative composition and uses thereof A purgative composition containing a purgative effective amount of a halogenated carbohydrate is disclosed. ... 11/02/06 - 20060247179 - Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof , or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, pharmaceutical compositions comprising the ... 10/26/06 - 20060241058 - Acetyl l-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day. ... 10/19/06 - 20060234954 - Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides This invention relates to to substituted benzimidazole-O glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. ... 10/19/06 - 20060234953 - Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders. ... 10/19/06 - 20060234952 - Combination therapy for effecting weight loss and treating obesity The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also ... 10/19/06 - 20060234951 - Combination therapy for effecting weight loss and treating obesity The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also ... 10/19/06 - 20060234950 - Combination therapy for effecting weight loss and treating obesity The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also ... 10/19/06 - 20060234949 - Adduct of topiramate and tramadol hydrochloride and uses thereof This invention relates to a new pharmaceutically useful compound which is a stoichiometrically 1:1 adduct of tramadol hydrochloride and topiramate, and to the manufacture and use thereof. ... 10/12/06 - 20060229260 - Substituted fused heterocyclic c-glycosides This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. ... 10/12/06 - 20060229259 - Ai-2 compounds and analogs based on salmonella typhimurium lsrb structure This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in Salmonella typhimurium. The X-ray crystallographic data can be used in a drug discovery method. Additionally the invention provides AI-2 analogs based on this ... 10/12/06 - 20060229258 - Steroidal compositions containing hydroxycarboxylic acids and methods of using the same Pharmaceutical compositions suitable for topical administration comprising two active ingredients, a hydroxycarboxylic acid and prednicarbate, and a pyrrolidone carboxylate salt moisturizing agent. In a particular aspect, the two active ingredients in the present inventive compositions have a purity of at least 90% and a concentration of degradation product(s) less than ... 10/05/06 - 20060223763 - C-glycoside compounds for stimulating the synthesis of glycosaminoglycans C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and/or keratinocytes. ... 10/05/06 - 20060223762 - Treatment of migraine A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula: ... 09/28/06 - 20060217323 - Substituted indazole-o-glucosides Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. ... 09/28/06 - 20060217322 - Xanthurenic acid derivative pharmaceutical compositions and methods related thereto or a prodrug or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. ... 09/21/06 - 20060211633 - D-mannose contraceptives The present invention concerns the use of D-mannose to prevent or inhibit uniting of sperm and egg/zygote in the conception process, both for specific target animals as well as general animal populations. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will ... 09/21/06 - 20060211632 - Pxr agonists for cardiovascular disease A method of treating or preventing coronary artery disease in an animal includes increasing blood serum apoA1 level in the animal by administering an effective amount of an agonist of the orphan nuclear receptor PXR. A method of identifying a substance useful for treating or preventing coronary artery disease in ... 09/21/06 - 20060211631 - Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin b1 The infusion preparation for peripheral parenteral administration comprises an infusion (A) containing glucose with 80 to 200 g/L concentration, and an infusion (B) containing amino acid with 50 to 150 g/L concentration. The infusion (A) and the infusion (B) are separately put into a vessel that is divided with an ... 09/14/06 - 20060205678 - Treatment of symptoms associated with irritable bowel syndrome Methods are provided for use in treating humans suffering from irritable bowel syndrome. In the subject methods, an effective amount of a nerve-acting agent, e.g., lidocaine, topiramate, mexiletine and gabapentin, etc. is administered to a human suffering from irritable bowel syndrome. Also provided are pharmaceutical compositions and kits for use ... 09/14/06 - 20060205677 - Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use Platinum containing compounds exhibiting cytostatic activity, methods of synthesizing platinum-containing compounds exhibiting cytostatic activity pharmaceutical compositions comprising platinum containing compounds, and methods of using such compounds and compositions for treating cancer are disclosed. ... 09/14/06 - 20060205676 - Pyridine derivatives in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 ... 08/31/06 - 20060194743 - Method for inhibiting acrylamide formation and use thereof An object of the present invention is to establish a method for actively suppressing the formation of acrylamide, which is formed by heating edible materials at a relatively high temperature, and uses thereof, and to provide more safe compositions such as foods, beverages, cosmetics, pharmaceuticals, and intermediates thereof. The present ... 08/24/06 - 20060189548 - Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders. ... 08/24/06 - 20060189547 - Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, ... 08/24/06 - 20060189546 - Compounds for treating autoimmune and demyelinating diseases Definitions for the variables are provided therein. ... 08/24/06 - 20060189545 - Novel chemical entities and methods for their use in treatment of metabolic disorders Methods and composition for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compounds to said patient at a level to ... 08/03/06 - 20060172954 - Systems and methods for dextrose containing peritoneal dialysis (pd) solutions with neutral ph and reduced glucose degradation product The invention provides container systems, kits and methods for peritoneal dialysis (PD) solutions. Such a system, for example, includes a first compartment that contains a Pt) osmotic agent and a second compartment that contains a PD buffer agent. The compartments maintain their respective contents separately from one another for purposes ... 08/03/06 - 20060172953 - Treatment of benign prostatic hyperplasia using energolytic agents The invention provides a method for treatment or prophylaxis of benign prostatic hyperplasia by administration of an agent that interferes with energy metabolism, particularly the production of ATP and NADH/NADPH, in prostate epithelial cells. ... 07/27/06 - 20060166902 - Derivative of glucose and of vitamin f, compositions comprising it, uses and preparation process An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for ... 07/27/06 - 20060166901 - Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids The embodiments described herein include a composition and method of treatment using compositions that include at least one O-acetylsalicyl derivative. The compositions and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems. ... 07/27/06 - 20060166900 - Salt of morphine-6-glucuronide Hydrobromide salt of morphine-6-β-D-glucuronide (M6G.HBr), a medicament, and a pharmaceutical composition comprising the M6G.HBr are disclosed. Methods of treating diseases using M6G.HBr, use of M6G.HBr as a medicament, in particular as an analgesic, are provided. Methods of making M6G.HBr and pharmaceutical compositions comprising the M6G.HBr also are provided. ... 07/27/06 - 20060166899 - Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc.; Z represents CO or SO2; R4 and ... 07/20/06 - 20060160751 - 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism The present invention provides a method for increasing the efficacy of antifolates which act via inhibition of dihydrofolate reductase (DHFR). The method comprises the steps of administration of 5-amino-4-imidazolecarboxamide riboside (Z) or its base with the antifolate such that the targeted cells are exposed to both the antifolate and Z ... 07/20/06 - 20060160750 - Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite ... 07/13/06 - 20060154875 - Thienoisoquinoline-phenylsulfonamides and their use as er-nfkappab inhibitors wherein R1 to R7 are as defined in the specification; or a pharmaceutically acceptable salt thereof. ... 07/13/06 - 20060154874 - Treatment of symptoms associated with bacterial vaginosis The invention relates to the use of saccharide, such as lactose for the preparation of a medicament for the treatment and/or prophylaxis of one or more symptoms caused by bacterial vaginosis, wherein the medicament comprises at least 20 percent by weight of saccharide, and wherein the medicament is substantially free ... 07/13/06 - 20060154873 - Aseptic combination preparation There is provided an aseptic combination preparation to be mixed at the time of use, characterized in that the same medicinal ingredients are divided and preserved in two or more chambers. The aseptic combination preparations according to the present invention are a mixing type at the time of their use ... 07/06/06 - 20060148722 - Novel lincomycin derivatives possessing antibacterial activity Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed. ... 07/06/06 - 20060148721 - Combination therapy for the treatment of dyslipidemia The present invention relates to compositions comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering ... 06/29/06 - 20060142209 - Glucopyranosyloxypyrazole derivatives and medicinal use thereof while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a ... 06/29/06 - 20060142208 - Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic ... 06/29/06 - 20060142207 - Compositions and methods for treating cancer Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells. ... 06/29/06 - 20060142206 - Novel difluorinated gem compounds, preparation methods thereof and applications of same This invention relates to a mini-type electric vehicle, which is mainly used for individual person or traffic in a certain field. It includes frame, seat, front & rear wheel, driving device, battery, steering system and front wheel suspension device. A casing, where the battery is placed on, protrudes forward at ... 06/22/06 - 20060135440 - Use of ribose to alleviate rhabdomyolysis and the side effects of statin drugs A method of alleviating the symptoms of rhabdomyolysis or the side effects of statin DRUG administration is disclosed. The method comprises the administration of D-ribose in doses of three to ten grams at least twice a day until the symptoms or side effects are alleviated. ... 06/22/06 - 20060135439 - Remedy for nerve damage The present invention provides a therapeutic agent for nerve damages such as those caused by spinal cord injury or nerve trauma, which comprises, as an active ingredient, a low-molecular-weight saccharide composed of at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof. The present invention also provides a ... 06/15/06 - 20060128638 - Texaphyrin coordination compounds and uses thereof Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed. ... 06/15/06 - 20060128637 - Phenolic acid complexes of hyoscyamine and process for preparing the same The present invention provides a novel tannate complex of hyoscyamine for human and veterinary pharmaceutical use. Tannate complexes of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. A process for preparing the tannate complex of hyoscyamine is provided. ... 06/15/06 - 20060128636 - Breast cancer resistance protein (bcrp) inhibitor [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 ... 06/15/06 - 20060128635 - Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same and the other represents —(CH2)n—Ar wherein Ar represents an optionally substituted C6-10 aryl group or an optionally substituted C1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C2-9 heterocycloalkyl group or an ... 06/08/06 - 20060122127 - Methods for reducing the side effects associated with mirtzapine treatment Compositions, and methods of use thereof, are provided for the prevention or treatment of side effects associated with the use of drugs that act as 5HT2/5HT3 serotonin receptor antagonists and alpha-2 adrenergic receptor antagonists (5HT2/5HT3 antagonist/alpha-2 antagonist). The method involves using dopamine-releasing compounds, such as amantadine, anticonvulsants, such as zonisamide, ... 06/08/06 - 20060122126 - C-glycoside derivatives and salts thereof The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent ... 06/01/06 - 20060116330 - Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose Disclosed herein are methods of using glucose anti-metabolites to alter utilization of glucose or other energy sources and to mimic metabolic effects of caloric restriction. In particular, in one embodiment herein, methods of enhancing longevity in an animal are described, the methods comprising administration of a composition comprising a glucose ... 06/01/06 - 20060116329 - Halothenoyl-cyclopropane-1-carboxylic acid derivatives Compounds of formula (I) wherein R is hydroxy, linear or branched C1-C6 alkoxy, phenoxy, benzyloxy, a group —N(R1R2) wherein R1 is hydrogen, linear or branched C1-C4 alkyl, benzyl, phenyl and R2 is hydrogen or linear or branched C1-C4 alkyl, or R is a glycoside residue or a primary alkoxy residue ... 05/25/06 - 20060111305 - Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof wherein the various substituents are defined herein. The invention also provides pharmaceutical compositions including compounds of formula I, methods of making such compounds, and methods of using such compounds. ... 05/18/06 - 20060105966 - Novel anticonvulsant derivative salts The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy. ... 05/18/06 - 20060105965 - Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations The present invention provides compositions and methods related to enhancing energy levels in an individual. The invention also provides methods for reducing the effects of stress in an individual. Certain embodiments of this invention include a composition comprising niacin bound chromium, D-ribose, a withanolide and an amine selected from the ... 05/18/06 - 20060105964 - Piperazine derivatives useful as ccr5 antagonists R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists ... 05/18/06 - 20060105963 - Therapeutic agents for inhibiting and/or treating vaginal infection A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis), Candida (e.g., Candida albicans), and/or Trichomonas (e.g., Trichomonas vaginalis) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the ... 05/18/06 - 20060105962 - Tonic to maintain intestinal flora An orally-administered pre-biotic composition for promoting the growth of normal, healthy intestinal flora while preventing the proliferation of unhealthy and toxic intestinal flora. When ingested, the composition improves the natural biological protection of the human body against toxic substances that are present in foods ingested and those that are produced ... 05/18/06 - 20060105961 - Method of using a cox-2 inhibitor and a topoisomerase ii inhibitor as a combination therapy in the treatment of neoplasia The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and a topoisomerase II inhibitor. ... 05/11/06 - 20060100162 - Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose A method of obtaining beneficial biological results associated with caloric restriction may be gained by administration of a composition containing at least one active agent which blocks metabolism of glucose as a source of energy in cells in glucose metabolism blocking effective amounts to an animal in need thereof. ... 05/04/06 - 20060094667 - Glucopyranosyloxypyrazole derivatives and use thereof in medicines (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo (lower alkyl) group or a halogen ... 04/27/06 - 20060089316 - Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels ... 04/13/06 - 20060079464 - Peritoneal dialysate containing taurine [Purpose] It is an objective of the present invention to provide a stable neutral peritoneal dialysate that contains a substance other than glucose to serve as an osmotic agent. [Means to solve the problem] The peritoneal dialysate of the present invention is stable and can be provided in the form ... 04/06/06 - 20060074031 - D-pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture wherein the groups R1 to R5, X, Z and R7a, R7b, R7c are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders. ... 04/06/06 - 20060074030 - Cyclopamine analogues and methods of use thereof The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of ... 04/06/06 - 20060074029 - Topical antimicrobial composition having improved moisturization properties The invention described herein provides an extended resident topical antimicrobial composition comprising an active antimicrobial and moisturizing ingredients that meets antimicrobial efficacy requirements and improves the condition of the user's skin as well. The composition of the invention achieves desired antimicrobial efficacy and therapeutic effect and still exhibits a relatively ... 03/30/06 - 20060069041 - Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents The present invention discloses hydrophilic derivatives of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same. ... 03/30/06 - 20060069040 - Ghb compositions The invention provides a combination of sodium gamma-hydroxybutyrate (GHB) or a prodrug or an analog thereof, with a compound that inhibits the metabolism of the GHB or GHB analog in vivo, thus prolonging or enhancing the bioactivity thereof. ... 03/30/06 - 20060069039 - Treatment of dyskinesia The present invention relates to the treatment of dyskinesia with compounds of General Formula (I) such as topiramate. The compound may be topiramate or a derivative thereof. The dyskinesia may be associated with a basil ganglia-related movement disorder such as parkinsonism and may also arise as a side-effect of other ... 03/23/06 - 20060063722 - C-aryl glucoside sglt2 inhibitors and method A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent. ... 03/23/06 - 20060063721 - Ai-2 compounds and analogs based on salmonella typhimurium lsrb structure This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in Salmonella typhimurium. The X-ray crystallographic data can be used in a drug discovery method. Additionally the invention provides AI-2 analogs based on this ... 03/23/06 - 20060063720 - Oxaliplatin solution concentrate The invention relates to oxaliplatin-containing infusion solution concentrates that include a physiologically-compatible carbohydrate as the solubilizer. The solutions and solution concentrates according to the invention are distinguished in that they are highly stable when stored, easy to handle, and well-tolerated. ... 03/16/06 - 20060058243 - Methods and compositions for treating diabetes mellitis Methods for modulating diabetes, impaired glucose tolerance, gestational diabetes and glucose resistance in a mammal, particularly a human. In one embodiment the method comprises administering a gallotannin composition to a mammal in need of the same. The gallotannin composition comprises one or more select hydrolysable gallotannins. In another embodiment the ... 03/09/06 - 20060052317 - Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also ... 03/09/06 - 20060052316 - Ceramide derivatives as modulators of immunity and autoimmunity α-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are ... 03/02/06 - 20060046968 - Prodrug substituted benzoxazoles as estrogenic agents Q, Q2, R1, R2, R2a, R3, R3a, and X as defined in the specification, or a pharmaceutically acceptable salt thereof. ... 02/23/06 - 20060040874 - Process for the preparation of topiramate The present invention relates to a process for the preparation of topiramate, intermediates in this process and a process for the preparation of these intermediates. ... 02/23/06 - 20060040873 - Composition for use in prophylaxis and or treatment The present invention relates generally to a composition for use in the prophylaxis and/or treatment of pain. More particularly, the present invention relates to a composition for use in the prophylaxis and/or treatment of chronic neuromuscular pain. The composition of the present invention is particularly useful in the prophylaxis and/or ... 02/16/06 - 20060035842 - Ophthalmic composition It is an object of the present invention to provide an ophthalmic composition, wherein: the ophthalmic composition assures a sufficiently high degree of safety to eyes of the lens wearer; the ophthalmic composition reduces symptoms such as an unpleasant feeling or dryness of the eyes; the ophthalmic composition does not ... 02/16/06 - 20060035841 - D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture wherein the groups R1 to R6, Z, X, Cy and R7a, R7b and R7c are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders. ... 02/16/06 - 20060035840 - Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof wherein X1 represents Nor CR1; X2 represents Nor CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a ... 02/02/06 - 20060025352 - Glucopyranosyloxypyrazole derivatives and use thereof in medicines (wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; ... 02/02/06 - 20060025351 - Cancer treatment including glycolytic inhibitors Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments ... 02/02/06 - 20060025350 - Oligosaccharide derivative wherein A represents a group such as a cyclic group, R1 and R2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or ... 02/02/06 - 20060025349 - D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture wherein the groups R1 to R6, Z, Cy and R7a, R7b, R7c, R7d are defined as in claim 1, have an inhibiting effect on the sodium-dependent glucose cotransporter SGLT. The present invention also relates to pharmaceutical compositions for the treatment of metabolic disorders. ... 01/26/06 - 20060019906 - Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor wherein each symbol is as defined in the specification. The present invention also relates to a pharmaceutical composition containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; an integrase inhibitor, an antiviral agent, anti-HIV agent, and the like, which contains the 4-oxoquinoline compound or ... 01/12/06 - 20060009399 - Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors The present invention provides methods for the treatment of obesity using sterol or 5α-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5α-stanol absorption inhibitors and at least one obesity control medication. ... 01/05/06 - 20060003946 - Tetraphenylbacteriochlorin derivatives and compositions containing the same (wherein, R is a hydrogen or a protecting group)], or its salt. The tetraphenylbacteriochlorin derivative or its salt has a large molar extinction coefficient at long wavelengths which are expected to have a high tissue-penetrating property, and exhibits high selectivity to tumor cells and hydrophilicity. ... 01/05/06 - 20060003945 - Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. ... 12/29/05 - 20050288236 - Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death This patent discloses a composition comprising a substituted fullerene, wherein the substituted fullerene comprises a fullerene core (Cn), wherein n is an even integer greater than or equal to 60, and at least one substituent group bonded to at least one carbon atom of the fullerene core, and at least ... 12/15/05 - 20050277598 - Method for improving ventilatory efficiency A method for improving ventilatory efficiency, comprising the administration of a pentose is disclosed. The most preferred pentose is D-ribose, to be administered in a dosage of from two to ten grams, one to four times daily for at least a week, but most preferably long term. ... 12/08/05 - 20050272670 - Synthesis and use of glycodendrimer reagents The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also a method of producing the chemically modified mutant ... 12/08/05 - 20050272669 - Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB ... 12/01/05 - 20050267047 - Diarylalkanes as potent inhibitors of binuclear enzymes The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or ... 12/01/05 - 20050267046 - Geldanamycin compounds and method of use where Q1, L, L1, R5, R6, and R11 are as defined herein, are useful for treating a disease or disorder ameliorated by inhibiting the function of extracellular heat shock protein-90. ... 12/01/05 - 20050267045 - Method for preparing peritoneal dialysate Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds ... 11/24/05 - 20050261206 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in ... 11/24/05 - 20050261205 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in ... 11/17/05 - 20050256059 - Methods and compositions for treatment of neurological disorder The present invention provides methods and compositions for producing a neurosalutary effect in a subject useful in treatment of neurological disorders, including retinal and optic nerve damage, in a subject in need thereof. The method includes administering to a subject a therapeutically effective amount of a hexose, such as mannose. ... 11/10/05 - 20050250708 - Novel c-glycosides, uses thereof The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesising them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously ... 11/03/05 - 20050245462 - Treatment of cancer with 2-deoxyglucose The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy. ... 11/03/05 - 20050245461 - Methods for treating alcoholism In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention ... 11/03/05 - 20050245460 - Methods and compositions for the treatment of epilepsy, seizure disorders, and other cns disorders The present invention relates to methods and compositions for treating CNS-related disorders. ... 11/03/05 - 20050245459 - Method of utilizing physiological activity of rare saccharide and composition containing rare saccharide A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of ... 10/27/05 - 20050239717 - Higher fullerenes useful as radical scavengers Chemically functionalized fullerenes are useful in various applications as radical scavengers. These chemically functionalized fullerenes offer the advantages of preservation of the high innate radical scavenging efficiency of the fullerene cage and ease of synthesis of fullerene derivatives of desirably altered chemical and physical properties and single isomers. Further, they ... 10/20/05 - 20050233982 - Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof R1 to R6 are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on the sodium-dependent glucose cotransporter SGLT2, the use thereof for ... 10/06/05 - 20050222048 - Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases R5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can ... 09/29/05 - 20050215488 - Novel lincomycin derivatives possessing antibacterial activity Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. The compounds of the subject invention may exhibit potent activities against bacteria, including Gram positive organisms, and may be useful antimicrobial agents. Methods of synthesis and of use of the compounds are also disclosed. ... 09/29/05 - 20050215487 - Conjugates comprising an nsaid and a sugar and uses thereof Disclosed are conjugates comprising an NSAID and a sugar and uses thereof, e.g. for treating or preventing pain, fever and any condition characterized by an inflammatory process. ... 09/22/05 - 20050209167 - Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the ... 09/22/05 - 20050209166 - Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture where the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders. ... 09/22/05 - 20050209165 - 4-biarylyl-1-phenylazetidin-2-ones represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents. ... // - 4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula - ... 09/15/05 - 20050203032 - Compositions for vaginal treatment The invention provides mannose phosphate and salts thereof for increasing vaginal cell growth, vaginal cell maturation and vaginal moisture, as well as compositions, articles and methods for treating and preventing vaginal conditions characterized by poor vaginal cell growth, low vaginal cell differentiation and low vaginal moisture. ... 09/01/05 - 20050192233 - Composition of matter comprising a lanolin free absorption base and method of making A composition of matter comprises a lanolin free absorption base. The absorption base in includes a superior lanolin free emulsifier selected for its HLB (hydrophilic-lipophilic balance) compatibility, neutral, nonionic absorption base ideal for the incorporation of many active ingredients. Use of this emulsifier permits low production temperatures during base manufacture, ... 08/04/05 - 20050171026 - Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction The present invention provides a composition of treating, preventing abnormal splicing caused by the excessive kinase induction, which comprises TG003 and a method using the same of treating, preventing abnormal splicing caused by the excessive kinase induction. ... 07/07/05 - 20050148517 - Carotenoid ether analogs or derivatives for controlling connexin 43 expression A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a ... 06/30/05 - 20050143322 - Method for treating obesity The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or ... 06/23/05 - 20050137144 - Method for treating obesity The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or ... 06/23/05 - 20050137143 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in ... 06/16/05 - 20050130910 - Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets The present invention relates to immobilized N-substituted tricyclic 3-aminopyrazole compounds of Formula 1 as tools for the identification of bimolecular targets in cells of therapeutic significance, profiling the selectivity of compounds, prediction of possible related toxicities and exploration of mechanisms of action in biological systems for therapeutic indications related to ... 06/16/05 - 20050130909 - Dalbavancin compositions for treatment of bacterial infections The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Compositions comprise a mixture of dalbavancin multimer and ... 06/16/05 - 20050130908 - Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof Disclosed are glycosides, orthoester glycosides and glycuronamides of fluoxetine and analogs thereof to treat conditions and diseases such as depression. ... 06/09/05 - 20050124558 - Ultrafine-l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same L-carnitine which has a particle size such that it substantially passes through a 100 USBS mesh sieve exhibits an increased bioavailability, a decreased hygroscopicity, and may be conveniently formulated with oil-based materials. ... 06/09/05 - 20050124557 - Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia The use of an ileal bile acid transport (IBAT) inhibitor and the use of a combination of an IBAT inhibitor and an HMG CoA reductase inhibitor in the treatment of a warm-blooded animal, such as man, with hypercholesterolemia and/or other forms of dyslipidaemia wherein said hypercholesterolemia and dyslipidaemias are characterized ... 06/09/05 - 20050124556 - Chromogenic enzyme substrates This invention provides novel chromogenic enzyme substrates which are indoxyl β-D-ribofuranosides. A process for their production is provided. Methods for detecting β-D-ribofuranosidase activity are given. The advantages of these novel compounds includes: detecting β-D-ribofuranosidase activity with high sensitivity and low substrate concentrations and use with other enzyme indicators in situations ... 06/09/05 - 20050124555 - Azulene derivatives and salts thereof The present invention provides an azulene derivative and a salt thereof, wherein an azulene ring is bonded to a benzene ring directly or via a lower alkylene which may be substituted with a halogen atom and the benzene ring is directly bonded to the glucose residue, and it is usable ... 06/02/05 - 20050119191 - Drugs, foods or drinks with the use of algae-derived physiologically active substances foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity ... ### FreshPatents.com Support - Terms & Conditions |